Generic Name
norethindrone acetate transdermal
Brand Names
CombiPatch, Junel
FDA approval date: August 07, 1998
Classification: Progestin
Form: Patch, Tablet
What is CombiPatch (norethindrone acetate transdermal)?
CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
